HLA B7 Antikörper (PE)

Produktnummer ABIN1111104

Produktdetails anti-HLA B7 Antikörper (PE)

Target: HLA B7 (HLA Class I B7 Alpha (HLA B7))

Reaktivität: Human, Non-Human Primate

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser HLA B7 Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS)

Verwendungszweck: Anti-HLA-B7 PE

Spezifität: The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.

Kreuzreaktivität (Details): Human, Non-Human Primates

Aufreinigung: Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Immunogen: Papain solubilised HLA-A2, B7

Klon: BB7-1

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μL reagent / 100 μL of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Rekonstitution: No reconstitution is necessary.

Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Do not freeze.
Avoid prolonged exposure to light.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

Referenzen für anti-HLA B7 Antikörper (PE) (ABIN1111104)

Cortez-Gonzalez, Sidney, Adotevi, Sette, Millard, Lemonnier, Langlade-Demoyen, Zanetti: "Immunogenic HLA-B7-restricted peptides of hTRT." in: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).

Hofmann, Glückmann, Kausche, Schmidt, Corvey, Lichtenfels, Huber, Albrecht, Karas, Herr: "Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS." in: Molecular & cellular proteomics : MCP, Vol. 4, Issue 12, pp. 1888-97, (2005) (PubMed).

de la Salle, Saulquin, Mansour, Klayme, Fricker, Zimmer, Cazenave, Hanau, Bonneville, Houssaint, Lefranc, Naman: "Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP)." in: Clinical and experimental immunology, Vol. 128, Issue 3, pp. 525-31, (2002) (PubMed).

Rini, Selk, Vogelzang: "Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 10, pp. 2766-72, (1999) (PubMed).

Trapani, Vaughan, Tait, McKenzie: "Immunoradiometric assay for the rapid detection of HLA-B27." in: Immunology and cell biology, Vol. 66 ( Pt 3), pp. 215-9, (1991) (PubMed).

Storkus, Alexander, Payne, Dawson, Cresswell: "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 7, pp. 2361-4, (1989) (PubMed).

Details zu HLA B7

Target: HLA B7 (HLA Class I B7 Alpha (HLA B7))

Andere Bezeichnung: HLA-B7 (HLA B7 Produkte)

Hintergrund: HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22 % of healthy Caucasian individuals.

Pathways: Human Leukocyte Antigen (HLA) in Adaptive Immune Response